Skip to main content

Resectoscope

The resectoscope is a specialized endoscopic system combining a sheath, working element, compatible electrode and telescope. It is an operative platform for transurethral resection in the lower urinary tract (TURP, TURBT, bladder-neck incision) and transcervical or intrauterine resection in gynecology (hysteroscopic myomectomy, polypectomy, septum incision, endometrial ablation). Continuous-flow sheaths are common but model-specific; a monopolar electrode cannot simply be exchanged for a bipolar one without matching the working element, generator and irrigant.[18][19] TURP remains an important comparator for newer BPH technologies and bladder-tumor resection techniques.[1][2]

Components​

ComponentDetail
Outer sheathIrrigation inflow/outflow according to the model; continuous-flow designs are common. 24–28 Fr is a common urologic range, not a universal size.
Inner sheath / working elementHouses the cutting loop; spring-loaded thumb-driven mechanism converts hand squeeze into in/out loop motion (newer designs add lateral rotation)
Cutting loop / electrodeWire loop carrying monopolar or bipolar RF energy; vaporization-roller / bar variants for ablation
TelescopeRigid rod-lens (12° or 30°); couples to a video camera
Irrigation systemContinuous-flow (Iglesias 1975) — simultaneous inflow + outflow keeps the field clear at low intracavitary pressure

Monopolar vs Bipolar​

FeatureMonopolarBipolar
IrrigantElectrolyte-free (1.5% glycine, 3% sorbitol)Normal saline
Classic hyponatremic TUR syndromeRisk with absorption of electrolyte-free fluidSubstantially reduced, not zero in pooled trials: Cochrane estimated 20 fewer events per 1,000 with bipolar TURP.[3]
TransfusionRisk varies by cohort and techniqueCochrane estimated 28 fewer transfusions per 1,000 with bipolar TURP.[3]
Catheterization / irrigation durationReferenceShorter (about 22 h less catheterization and 9 h less irrigation in Mamoulakis 2009)[4]
Symptom / QoL outcomeEquivalentEquivalent

Both monopolar and bipolar TURP remain guideline-supported in appropriately selected patients. Bipolar systems permit saline irrigation and probably reduce classic TUR-syndrome and transfusion events, but saline absorption can still cause volume overload or hyperchloremic acidosis; monitor distension or irrigation fluid according to the procedure and local protocol.[3][4][20][21]

Reconstructive-Urology and Functional-Urology Uses​

The resectoscope is encountered in WARWIKI scope across three pathways:

TURP — reference standard for BPH​

  • Indications. Moderate-to-severe LUTS refractory to medical therapy, refractory retention, recurrent UTI from BPO, bladder stones, gross hematuria of BPH origin, renal insufficiency from BPO.[1][2]
  • Outcomes. Mean IPSS improvement 12–15 points, mean Qmax increase of approximately 162%; retreatment rate 3–14.5% at 5 years.[2][5]
  • Position in the BPH algorithm. EAU positions TURP for 30–80 mL prostates. AUA 2026 Statement 37 (Strong Recommendation; Evidence Level Grade A) says clinicians should offer bipolar or monopolar TURP as an option, and TURP is the benchmark against which water vapor, PUL, aquablation, PAE and HoLEP / ThuLEP are compared.[1][2]

TURBT — out-of-scope as a primary oncology topic, included briefly because the instrument is the same​

  • Quality determinants that drive downstream decisions: complete resection, clear operative documentation and detrusor muscle in the specimen where required.[7][18] The current EAU NMIBC guideline recommends (Strong) repeat TURBT after incomplete or doubtfully complete resection, absent detrusor muscle except Ta low-grade/G1 and primary CIS, or any T1 tumour, and (Weak) timing it 2–6 weeks after the initial resection, including the primary tumour site. Size or multifocality alone is not listed as a universal repeat-TURBT trigger. An older high-grade Ta/T1 synthesis found 51% persistence and 8% T1 understaging; a more contemporary 81-study synthesis reported 31.4% residual disease and 2.8% upstaging in T1, so neither pair is an all-comer risk.[18]
  • En-bloc resection (ERBT). Teoh 2024 phase-3 RCT (≤ 3 cm tumors) reported 1-yr recurrence 29% versus 38% with conventional TURBT (p = 0.007); Xu 2025 meta of 12 RCTs (n = 2,097) found higher detrusor sampling (OR 1.90), lower perforation (OR 0.30) and lower obturator-reflex (OR 0.18). EAU gives a Strong recommendation to perform en-bloc or fractioned resection, without preferring either, and notes that ERBT's overall superiority remains debated because other RCTs and reviews did not reproduce a recurrence advantage.[8][9][10][18]

Hysteroscopic resectoscope — urogyn-shared use​

  • Submucosal myoma, endometrial polyp, uterine septum, intrauterine adhesions, endometrial ablation. ACOG endorses direct hysteroscopic removal over blind procedures for polypectomy; the mini-resectoscope extends feasibility to the office setting.[11][12]
  • Loop resectoscope versus hysteroscopic tissue-removal systems (morcellators). Morcellators are faster and more complete for polyps and type 0–I myomas; the loop resectoscope retains the advantage for type II (deeply embedded) myomas where loop dissection is needed.[11]

Complications of TURP — the RU-relevant Long-Tail​

Modern TURP complication rates vary with patient, platform and follow-up. The events most relevant to reconstructive practice downstream are urethral stricture, bladder-neck contracture and post-TURP incontinence:[2][3][13][14]

ComplicationContemporary rateReconstructive implication
Mortality0.1%—
TUR syndrome0–1.4% (near-zero bipolar)—
Transfusion0.4–2.9%—
Clot retention2–5%May need 3-way irrigation catheter
Urinary retention after catheter removal3–5.8%Often detrusor failure, not incomplete resection
Urethral stricture2.2–9.8%Drives downstream DVIU or urethroplasty; see Sachse urethrotome
Bladder-neck contracture0.3–9.2%Drives transurethral incision / resection of BNC; see Balloon Dilator; risk factors include small prostate volume and a positive preoperative urine culture[14]
Retrograde ejaculation~ 65%Expected; counsel preoperatively
Erectile dysfunction~ 6.5–10%—
Stress incontinence (late)0.5%Late SUI may need AUS, sling, or PAUS; early urge incontinence ~ 30–40% but transient
Retreatment3–14.5% at 5 yr—

For the reconstructive surgeon, post-TURP urethral stricture, BNC, and post-prostatectomy SUI are the operative downstream consequences that bring these patients to urethroplasty, transurethral BNC incision, AUS, and sling.

TURBT-Specific Technical Considerations​

  • Obturator-nerve reflex during lateral-wall resection causes sudden adductor contraction and risks bladder perforation. Consider an appropriate obturator block or anesthetic plan; bipolar energy alone does not reliably prevent the reflex or perforation in randomized comparisons.[15][22]
  • Enhanced visualization. Blue-light PDD and NBI improve detection of CIS and flat lesions missed under white light; see the rigid and flexible cystoscope pages for the BLC and NBI data.[6][16]
  • En-bloc resection energy sources. Bipolar, Ho:YAG, thulium, KTP or GreenLight, or hybrid knife; laser and hybrid-knife platforms show superior outcomes in network meta.[17]

Technique — TURP​

  1. Spinal or general anesthesia; dorsal lithotomy; cystoscopic survey.
  2. Continuous-flow video resectoscope (24–28 Fr) with bipolar working element (preferred) and 12° / 30° telescope.
  3. Systematic resection from bladder neck to verumontanum, leaving the verumontanum and external sphincter intact.
  4. Chips evacuated with Ellik evacuator or Toomey syringe; average resected mass approximately 28 g; incidental prostate carcinoma in approximately 10% of specimens.[13]
  5. 24–26 Fr 3-way Foley with 30 mL balloon for fossa tamponade and CBI for 24–72 h.

Limitations​

  • TUR syndrome risk persists with monopolar. Bipolar saline systems reduce it (Cochrane RR 0.17) and are the usual modern choice.
  • Prostate size ceiling. Large glands (typically > 80–100 g) increasingly handled by enucleation (HoLEP / ThuLEP) or open simple prostatectomy.
  • Reconstructive sequelae. Urethral stricture and bladder-neck contracture are the late events that bring TURP patients to RU clinic.
  • Hysteroscopic mini-resectoscope has expanded office feasibility but still requires distending media monitoring.

See also: Rigid Cystoscope, Flexible Cystoscope, Sachse Urethrotome (DVIU), Balloon Dilator, Three-Way Catheter (CBI), Electrosurgical Pencil, Bovie Tips.

References​

1. Wei JT, Dauw CA, Brodsky CN. "Lower urinary tract symptoms in men." JAMA. 2025;334(9):809–21. doi:10.1001/jama.2025.7045

2. Goueli R, Badlani GH, Welliver C, et al. "Management of lower urinary tract symptoms attributed to benign prostatic hyperplasia: AUA guideline (2026) part III: procedural / surgical management." J Urol. 2026. doi:10.1097/JU.0000000000005099

3. Alexander CE, Scullion MM, Omar MI, et al. "Bipolar versus monopolar transurethral resection of the prostate for lower urinary tract symptoms secondary to benign prostatic obstruction." Cochrane Database Syst Rev. 2019;12:CD009629. doi:10.1002/14651858.CD009629.pub4

4. Mamoulakis C, Ubbink DT, de la Rosette JJ. "Bipolar versus monopolar transurethral resection of the prostate: a systematic review and meta-analysis of randomized controlled trials." Eur Urol. 2009;56(5):798–809. doi:10.1016/j.eururo.2009.06.037

5. Franco JV, Jung JH, Imamura M, et al. "Minimally invasive treatments for lower urinary tract symptoms in men with benign prostatic hyperplasia: a network meta-analysis." Cochrane Database Syst Rev. 2021;7:CD013656. doi:10.1002/14651858.CD013656.pub2

6. Lenis AT, Lec PM, Chamie K, Mshs MD. "Bladder cancer: a review." JAMA. 2020;324(19):1980–91. doi:10.1001/jama.2020.17598

7. National Comprehensive Cancer Network. "Bladder Cancer." NCCN Clinical Practice Guidelines in Oncology. Updated 2026.

8. Teoh JY, Cheng CH, Tsang CF, et al. "Transurethral en bloc resection versus standard resection of bladder tumour: a randomised, multicentre, phase 3 trial." Eur Urol. 2024;86(2):103–11. doi:10.1016/j.eururo.2024.04.015

9. Xu Z, Wang Q, Li B, et al. "An updated systematic review, meta-analysis, and trial sequential analysis of the efficacy and safety of en bloc transurethral resection vs conventional transurethral resection for nonmuscle-invasive bladder tumor." Int J Surg. 2025;111(4):3061–77. doi:10.1097/JS9.0000000000002291

10. Li DX, Yu QX, Wu RC, et al. "Efficiency of transurethral en-bloc resection vs conventional transurethral resection for non-muscle-invasive bladder cancer: an umbrella review." Cancer Med. 2024;13(11):e7323. doi:10.1002/cam4.7323

11. Deutsch A, Sasaki KJ, Cholkeri-Singh A. "Resectoscopic surgery for polyps and myomas: a review of the literature." J Minim Invasive Gynecol. 2017;24(7):1104–10. doi:10.1016/j.jmig.2017.08.645

12. Etrusco A, Laganà AS, Chiantera V, et al. "Efficacy, safety, and feasibility of the treatment of intrauterine pathologies with the mini-resectoscope: a systematic review." Int J Gynaecol Obstet. 2024;166(2):527–37. doi:10.1002/ijgo.15393

13. Reich O, Gratzke C, Bachmann A, et al. "Morbidity, mortality and early outcome of transurethral resection of the prostate: a prospective multicenter evaluation of 10,654 patients." J Urol. 2008;180(1):246–9. doi:10.1016/j.juro.2008.03.058

14. Goßler C, Pfänder F, Haas M, et al. "Risk factors for bladder neck contracture after transurethral resection of the prostate." Prostate. 2023;83(11):1020–7. doi:10.1002/pros.24543

15. Wu J, Gao Y, Xiong Z, et al. "Comparison of different methods of obturator nerve block in transurethral resection of bladder tumors: a systematic review and network meta-analysis." Cancer Med. 2023;12(5):5420–35. doi:10.1002/cam4.5364

16. Richards KA, Smith ND, Steinberg GD. "The importance of transurethral resection of bladder tumor in the management of non-muscle invasive bladder cancer: a systematic review of novel technologies." J Urol. 2014;191(6):1655–64. doi:10.1016/j.juro.2014.01.087

17. Mi G, Ma Y, Liu L, Liao B, Wang K. "Optimal energy source selection strategies for en bloc resection in non-muscle invasive bladder cancer: a systematic review and network meta-analysis." World J Urol. 2025;43(1):155. doi:10.1007/s00345-025-05513-8

18. European Association of Urology. Non-muscle-invasive Bladder Cancer guideline, Diagnosis §§5.10, 5.13–5.15, accessed September 2026.

19. Cook Medical. Cook Single-Use RF Electrode instructions for use, T_CRFE_REV1, English pp. 3–4. Manufacturer IFU, monopolar device only; Karl Storz bipolar working-element specifications.

20. European Association of Urology. Management of Non-neurogenic Male LUTS guideline, Disease Management §5.3.1, accessed September 2026.

21. You AH, Lee JY, Choi JH, Kim MK. Hyperchloremic metabolic acidosis during bipolar TURP: two cases. J Int Med Res. 2021;49:3000605211024480. doi:10.1177/03000605211024480.

22. Venkatramani V, et al. Monopolar versus bipolar TURBT: a randomized controlled trial. J Urol. 2014;191:1703–1707. doi:10.1016/j.juro.2013.12.004.